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Background: Limited research has examined the impact of peanut allergy (PA) on 
children using validated instruments to assess psychosocial burden and the factors 
influencing burden.
Objective: The PAPRIQUA study aimed to assess the caregiver-reported impact of 
living with PA on children's health-related quality of life (HRQL), correlations be-
tween PA severity and child's sex, and associations of caregivers’ sex and anxiety 
with the proxy report of their child's HRQL and to identify significant predictors of 
a child's HRQL.
Methods: A cross-sectional survey of caregivers of children with mild, moderate and 
severe PA, based on caregiver perception, was conducted in the United Kingdom. 
Participants were recruited through a survey recruitment panel; a maximum quota 
of 20% who rated their child's PA as mild was set to ensure population diversity; 
however, the quota was not required as few participants considered their child's PA 
mild. The survey, funded by Aimmune Therapeutics, included sociodemographic 
and clinical questions, the EQ-5D-Y, Hospital Anxiety and Depression Scale, Food 
Allergy Quality of Life Questionnaire-Parent Form (FAQLQ-PF) and Food Allergy 
Independent Measure (FAIM).
Results: One hundred caregivers of children with PA (aged 4-15 years) completed the 
survey. Child's sex was not associated with proxy-reported burden. For younger chil-
dren (aged 4-10 years), there was no effect of PA severity; parents of older children 
(aged 11-15 years) reported low to higher burden for their child on the EQ-5D-Y and 
FAQLQ-PF dependent upon PA severity. For all measures of child burden except the 
EQ-5D-Y, two or more reactions in the past 12 months and parental anxiety signifi-
cantly predicted higher levels of burden for the child (P < .05–P < .001). Experiencing 
a life-threatening event in the past 12 months significantly predicted EQ-5D-Y proxy 
utility (P < .01).
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1  | INTRODUC TION
Peanut allergy (PA) affects up to 3% of children in the developed 
world,1 although prevalence estimates vary widely, with a recent 
Clinical Practice Research Datalink (CPRD) study suggesting the 
prevalence of PA in children in the United Kingdom (UK) is around 
0.6%.2,3 It is not easy to predict how sensitive an individual with PA 
may be; even ingestion of a small amount of peanut can trigger a 
reaction.4
Although several immunotherapies are under investigation for 
the prevention and management of PA, there is currently no ap-
proved treatment outside of the United States of America.5,6 As a 
result, the management of PA currently involves strict avoidance 
of peanuts and emergency treatment in the case of accidental 
ingestion.
A recent review found a growing body of evidence that demon-
strates that living with food allergy (FA) adversely affects children and 
families emotionally, socially and financially.7 In PA specifically, studies 
have compared the health-related quality of life (HRQL) of children with 
PA to the HRQL of children with other conditions or healthy siblings. 
Avery et al (2003), using an unvalidated PA quality of life (QoL) ques-
tionnaire and an adapted Vespid Allergy QoL questionnaire, found that 
children with PA reported poorer QoL, more fear of an adverse event 
and more anxiety about eating than children with insulin-dependent 
diabetes.8 King et al (2009) compared children with PA to their non-PA 
siblings using the generic Paediatric QoL Inventory (PedsQL) and the 
Spence Children's Anxiety Questionnaire.9 They reported that children 
with PA have significantly greater separation anxiety and poorer QoL 
in general, in school and in relation to their physical HRQL, compared 
to their siblings with no PA.
Many factors have been identified as having an influence on 
HRQL for children with FA. Perceived FA severity and objective in-
dicators of FA severity (history of anaphylaxis, number of symptoms 
experienced during a reaction) have been found to influence a child's 
HRQL in FA.10,11 In addition, having multiple FAs, severe symptoms 
and maternal depression, stress and anxiety have also been found to 
negatively impact a child's HRQL.11-13 No relationship has previously 
been reported between adrenaline auto-injector (AAI) prescription, 
reaction severity, or child sex and child HRQL.10,11,14,15 Conflicting 
findings on the relationship between children's age and HRQL have 
been reported, with one study finding that older children (aged 
6-12 years) had worse HRQL than children aged up to 5 years12 and 
another study showing no significant association between age and 
HRQL.11 In PA specifically, one study found that child anxiety and 
parenting stress (measured using the Parenting Stress Index) predict 
parent's proxy report of their child's HRQL, and child anxiety, par-
enting stress, length of diagnosis and AAI experience predict child's 
self-report of their HRQL.16 No studies have been identified investi-
gating the relationship between perceived disease severity or child 
sex and HRQL in PA specifically.
Previous research has suggested that caregivers’ sex is associ-
ated with their ratings of their child's HRQL. In a study of FA, both 
parents scored their food-allergic child's HRQL better than the 
child's own assessment, whereas mother-reported child HRQL was 
significantly correlated with limitations in the child's social life, and 
father-reported child HRQL was associated with limitations in the 
family's social life.14,15 In a study of families with a child with PA, 
mothers felt that there was a greater impact on HRQL for their pea-
nut-allergic child, compared to that reported by siblings, fathers or 
the peanut-allergic children themselves.9
Due to the limited PA-specific research exploring factors associ-
ated with child HRQL, and limited use of validated FA instruments to 
assess HRQL in PA, the objectives of this study were to (a) describe 
the caregiver-reported impact of living with PA on children's HRQL 
and evaluate the roles of PA severity and child sex; (b) explore how 
caregivers’ sex and anxiety are associated with the proxy report of 
their child's HRQL; and (c) identify significant predictors of a child's 
HRQL. This paper reports data from a survey conducted in the UK 
with parents of children aged 4 to 15 years. Given the age range 
of the children, the effect of age was also considered by splitting 
the sample for those aged 4-10 and 11-15 years, reflecting mean-




This study used a cross-sectional design to survey caregivers of chil-
dren and teenagers aged 4 to 15 years to provide reports of their 
child's HRQL. The study was reviewed and approved by the Freiburg 
Ethics Commission International (FECI) prior to participant recruit-
ment (FECI code: 017/1938; date: 20/11/2017).
Conclusions and Clinical Relevance: Caregivers report that children with PA experi-
ence high levels of psychosocial burden, particularly those with more severe PA and a 
reaction history. Interventions to decrease caregiver anxiety and reaction frequency 
may help reduce the child's burden. Self-report studies in children with PA would help 
confirm these findings.
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2.2 | Participants
Participants were recruited through a survey recruitment panel. 
Participants were eligible for the study if they were a parent or 
primary caregiver of a child (aged 4-15 years) with medically diag-
nosed PA who had experienced at least one reaction to peanuts 
in their day-to-day life (other than a food challenge). Participants 
were also asked to rate the severity of their child's PA using cat-
egories of mild, moderate or severe. In order to ensure diversity in 
the severity of PA in the sample, a quota was set for a maximum of 
20% of participants who perceived the severity of their child's PA 
as mild and a minimum of 80% who perceived their child's sever-
ity as moderate to severe. At least 25% of the moderate/severe 
samples were required to have used an AAI, and a minimum of 
10% were required to have experienced a life-threatening event. 
However, in the end, the sample quotas were achieved without the 
need to enrich or limit any numbers. All participants came from 
the UK.
2.3 | Procedures and measures
Eligible participants were informed that the study involved complet-
ing an online survey, was expected to take up to 30 minutes, and 
would be about their and their child's experiences of living with PA. 
Participants were asked to read the information provided, and if 
interested in participating were asked to give their consent online 
prior to completing the online survey. Participants received nominal 
reimbursement for participating in the study.
The survey consisted of sociodemographic questions about the 
caregiver and their child and clinical questions about the child's PA. 
Clinical questions included the caregiver's perception of the severity 
of their child's PA (mild, moderate or severe), how their child was 
diagnosed, caregiver's confidence in managing their child's reactions 
to PA (not at all confident to very confident), the number of reactions 
to peanut their child has experienced in the last 12 months and their 
lifetime, the type of treatment received in the last 12 months and 
their lifetime, and whether their child ever experienced a life-threat-
ening reaction to peanut. The survey also included proxy-reported 
measures of child HRQL (Proxy EQ-5D-Youth version, Food Allergy 
Quality of Life Questionnaire-Parent Form [FAQLQ-PF]), care-
giver and child expectation of outcome questions (Food Allergy 
Independent Measure-Parent Form [FAIM-PF]), and caregiver anxi-
ety and depression (Hospital Anxiety and Depression Scale [HADS]).
The EQ-5D-Y (proxy 1)17 is a validated generic health status 
measure.18 Participants report their child's current health on five di-
mensions (mobility, self-care, pain and discomfort, usual activities, 
anxiety and depression) from no problems to extreme problems. The 
responses are converted into a single index value where a score of 
1 represents full health and a score of 0 represents dead. As there 
are currently no value sets for use in children and teenagers, the 
UK value set was applied to score the instrument.19 Participants also 
rated their child's current health on a 0-100 visual analogue scale 
(VAS). To the best of our knowledge, this is the first study to show 
proxy-reported impacts of PA on the EQ-5D-Y.
The FAQLQ-PF20 is a 30-item questionnaire assessing three do-
mains (emotional impact, food anxiety, and social and dietary lim-
itations). Each item is scored on a 7-point scale ranging from 0 (no 
impact) to 6 (extreme impact); each domain is scored as an average 
of the items with the total score representing the mean of the do-
main scores. The instrument has been validated with internal con-
sistency of α = 0.91 (age 6-12) for the total score and α = 0.90-0.94 
for the domains (age 6-12).20 In a study of child-parent pairs, the 
FAQLQ-PF correlated moderately with the FAQLQ-CF (ICC = 0.57; 
P < .001),21 a self-report instrument for children aged 8-12 years, 
which is validated for patients with PA.22 The children's self-report 
scores were higher (worse) than those reported for them by their 
parents (P < .001).21
The FAIM-PF23 is usually used in conjunction with the FAQLQ 
and consists of eight items in total, four items related to the par-
ent's self-reported perception of their child's likelihood of allergic 
reaction events (accidentally ingesting the food to which they are 
allergic, having a severe reaction, dying from their FA, effectively 
treating themselves when needed) and the same four items related 
to the parent-reported perception of their child's beliefs. Each item 
is answered on a seven-point scale, with FAIM scores ranging from 
1 (low perceived disease severity) to 7 (high perceived disease se-
verity). Total FAIM scores were significantly correlated with FAQLQ 
scores for corresponding age groups, and with DBPCFC scores in 
peanut-allergic adults and teenagers, with a trend for children.22 The 
FAIM-PF was well correlated with the FAIM Child Form (FAIM-CF) in 
child-parent pairs (ICC = 0.80; P < .001).21
The HADS24 is a 14-item measure of anxiety and depression used 
in both hospital and community settings. The questionnaire gives 
clinically meaningful results as a psychological screening tool and 
can assess the symptom severity and “caseness” of anxiety disorders 
and depression in patients with illness and the general population. 
HADS provides separate scores for anxiety and depression domains. 
Scores for each domain range from 0 to 21, with scores of 0-7 in-
dicating “normal” or no anxiety or depression, 8-10 indicating mild, 
11-14 indicating moderate and 15-21 indicating severe anxiety or 
depression; scores of ≥11 indicate probable “caseness.”24 Population 
norms related to the proportion of people reporting probable clinical 
caseness in the UK (based on adults aged 25-65 years) have also 
been estimated at 12.5% (males) and 19% (females), with averages 
for males and females of 15.8% for anxiety and 6.9% for depres-
sion.25 The HADS has been validated many times in different popu-
lations, with internal consistency for the anxiety scale ranging from 
α = 0.68-0.93 (mean: 0.83) and the depression scale ranging from 
α = 0.67-0.90 (mean: 0.82).26
2.4 | Analysis
Demographic and clinical characteristics were analysed using de-
scriptive statistics. The FAQLQ-PF and HADS were scored according 
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to their published scoring instructions.20,24 The EQ-5D-Y was scored 
using the UK EQ-5D-3L adult value set.19 Pearson's, point biserial 
and Spearman's correlations were conducted as appropriate (based 
on scale response type and sample distribution) to explore relation-
ships between variables. Correlations were interpreted in line with 
Cohen's guidelines: small, 0.10-<0.30; moderate, 0.30-<0.50; and 
large, 0.50.27 To explore the impact of different variables on child 
burden, two-way analyses of variance (ANOVAs) and Kruskal-Wallis 
tests were conducted. To further explore which variables signifi-
cantly predicted child burden, multivariate ordinary least squares lin-
ear regression models were conducted, with each of the FAQLQ-PF 
domains and total score included as dependent variables in separate 
models. The number of reactions in the past 12 months and number 
of reactions in the child's lifetime were included as categorical vari-
ables in the regression analysis: 0, 1, 2 or more reactions in the past 
12 months, and 0-2, 3-5 and 6 or more reactions in their lifetime. 
Results of statistical tests were considered statistically significant 
if P-values were equal to or below .05. All analyses were conducted 
using STATA (version 16.0).
3  | RESULTS
The demographics and clinical characteristics of the participants 
and their children with PA are displayed in Table 1. The survey was 
completed by 100 caregivers of a child with PA; the sample con-
tained male (45%) and female (55%) caregivers, and female (42%) and 
male (58%) children with PA. Caregivers had a mean age of 39 years 
(standard deviation [SD]: 7.6; range 21-65) and their children had a 
mean age of 10 years (SD: 3.4; range: 4-15); nearly a quarter of chil-
dren had other food allergies in addition to PA and almost three-
quarters had been prescribed an AAI. Both parent and child samples 
had a high proportion of allergic rhinitis (parents: 22%; children: 
36%), asthma (parents: 20%; children: 34%) and skin disorders (par-
ents: 17%; children: 26%).
3.1 | Impact of PA on children's HRQL
Summaries of the impact of PA on the HRQL of children with PA, 
based on proxy-reported generic (EQ-5D) and FA-specific outcome 
measures (FAQLQ and FAIM) for the sample as a whole and by age 
and severity groups, are presented in Figure 1 and Table 2. All of 
the health outcome measures were significantly correlated with 
each other (r's = .30-0.68, P's < .01, excluding domains of the same 
measure), indicating medium to large effect sizes.26 The EQ-5D-Y 
mean scores show a lower mean utility value and VAS for the severe 
group (index: 0.768; VAS: 78.5) compared to mild (index: 0.863; VAS: 
81.7) or moderate (index: 0.909; VAS: 82.0). No population norms 
are available for the EQ-5D-Y; however, the population norm for 
young adults (aged 18-24 years, EQ-5D-3L) is 0.940.28 Therefore, 
the proxy-reported utility for the sample as a whole (0.873) is lower 
than the norm for young adults.
When considering age group, Figure 1 shows the younger age group 
consistently tracking below the EQ-5D utility population norm, showing 
a non-linear relationship with severity. The older age group only drop 
below population norms in the severe group and show a clear linear 












Allergic rhinitis 22 36
Asthma 20 34
Diabetes type 1/2 2/4 3/2
Eating disorders 7 6
Skin disorders 17 26
Stress 13 5
Other 2 4
None of the above 37 28
Other food allergies, n (%)
Yes - 24 (24.0)a 
No - 76 (76.0)
If Yes: Food allergy, n (%)
Celery - 2 (8.3)
Cow milk/dairy products - 6 (25.0)
Egg - 11 (45.8)
Fish/shellfish etc - 1 (4.2)
Soya beans/other legumes - 1 (4.2)
Other nuts - 11 (45.8)
Other - 5 (21.0)
Prescribed an AAI, n
Yes - 71
Experienced life-threatening event (lifetime, n)
Yes - 34
Number of reactions (lifetime)







Abbreviations: AAI, adrenaline auto-injector; N, sample size; SD, 
standard deviation.
a38% among those with caregiver proxy-reported severe peanut allergy. 
bIf two outliers are excluded (192 and 206 reactions) the mean (SD) is 
8.2 (8.6). 
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association between PA severity and HRQL. This was supported by 
Kruskal-Wallis test results showing a significant main effect of sever-
ity on EQ-5D-Y utility, showing that there was a significant difference 
in utility depending on the level of severity. While significant for the 
sample as a whole (X2 = 6.469, P < .05), when considering age group, 
it can be seen that this effect is driven by the older population (aged 
11-15 years: X2 = 7.802, P < .05). For the younger group, there was no 
significant difference in utility depending on proxy-rated severity of PA 
(aged 4-10 years: X2 = 1.565, P = .457). The EQ-5D VAS did not show a 
significant effect of PA severity for either group.
The FAQLQ total and domain scores also followed the same pat-
tern with regard to the proxy-reported severity of PA (Table 2). The 
FAQLQ results show a similar burden profile, insofar as the total age 
group means are similar, but reflect the parents of younger children 
reporting a more consistent level of moderate (FAQLQ scores of 
3-4) burden. For the younger age group, there was no main effect 
of PA severity (aged 4-10 years: X2 = 1.032-1.600; P's > .05), show-
ing no difference in the FAQLQ scores in relation to severity rating, 
whereas the parents of older children report low to higher burden 
dependent upon PA severity (FAQLQ scores of 2-5) with a significant 
main effect of PA severity on all FAQLQ domains (aged 11-15 years: 
X2 = 7.707-10.309; P's < .05). The FAIM total score did not signifi-
cantly differ across levels of PA severity for either age group. The 
sex of the child was not significantly associated with any outcome 
measures or proxy-reported PA severity (all r's < .13, all P's > .05). 
Similarly, there were no main effects of sex or interaction effects 
between sex and severity in the inferential analyses.
3.2 | Relationship between caregiver sex and 
anxiety and proxy report of child's HRQL
Descriptive statistics of the child HRQL outcomes by caregiver sex and 
HADS “probable clinical anxiety” are presented in Table 3. This shows 
that greater PA burden, as measured by the EQ-5D-Y, FAQLQ and FAIM, 
was reported amongst children whose caregivers had “probable clinical 
anxiety.” Caregiver sex was not significantly associated with caregiver 
“probable clinical anxiety” caseness (X2 = 0.718; P > .05) or mean anxi-
ety score as measured using the HADS (r = .07, P > .05) or significantly 
correlated with any of the child proxy-reported outcome measures 
(EQ-5D-Y, FAQLQ-PF, FAIM) (Appendix S1; r's = .02-0.13, P's > .05). 
However, caregiver mean anxiety was significantly associated with all 
child proxy-reported outcome measures, with moderate effect sizes 
(r's = .30-0.55, P's < .01). Relatedly, caregiver's mean anxiety was sig-
nificantly associated with the number of life-threatening events their 
child had experienced in the past 12 months (r = .25, P < .05) and the 
number of reactions their child had experienced in their lifetime (r = .23 
and r = .24, P's < .05, respectively). Furthermore, only caregivers with 
children considered to have moderate or severe PA reported levels of 
probable clinical anxiety higher than UK population norm values (33% 
versus 15.8%, respectively).25
Results from ANOVAs exploring main effects and interac-
tions showed a main effect of caregiver anxiety on EQ-5D-Y-VAS 
(F = 8.33, P < .01), FAQLQ-PF-Total (F = 24.02, P < .001), FAQLQ-EI 
(FAQLQ-Emotional Impact; F = 28.61, P < .001), FAQLQ-FA 
(FAQLQ-Food Anxiety; F = 17.99, P < .001), FAQLQ-SDL (FAQLQ-
Social and Dietary Limitations; F = 20.14, P < .001) and FAIM-CF 
(FAIM child version; F = 7.87, P < .01) but not on EQ-5D-Y utility 
(F = 3.67, P > .05). Having included the significant main effect of anx-
iety and interaction term, thus reducing error variance, the ANOVAs 
also showed that male caregivers reported that their children ex-
perience greater PA burden with a significant main effect of sex on 
FAQLQ-PF-Total (F = 4.75, P < .05), FAQLQ-EI (F = 6.25, P < .05) 
and FAQLQ-FA (F = 4.14, P < .05). There was no significant sex by 
anxiety interactions; the effect of caregiver anxiety on their child's 
proxy-reported QoL did not differ by sex.
3.3 | Predictors of HRQL in children with PA
Caregiver anxiety, caregiver confidence, PA severity, life-threaten-
ing events and number of reactions were significantly correlated 
with several measures of child burden (Appendix S1). Other poten-
tial predictors (AAI use, child's sex) were not significantly associated 
F I G U R E  1   EQ-5D-Y index by PA 
severity for the total sample and each 
age group. PA, peanut allergy; UK, United 
Kingdom
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with outcome assessments. Multivariate regression models for each 
outcome assessment are presented in Appendix S2 (only significant 
predictors rather than all predictors in the models are shown). As the 
number of reactions in the “past 12 months” and in the child's “life-
time” and life-threatening events are not independent of each other, 
these were run in separate models. The regression models show that 
for all measures of PA burden except the EQ-5D-Y proxy utility, the 
experience of two or more reactions in the past 12 months, and pa-
rental anxiety, are significantly associated with increased burden, 
after controlling for other covariates. Lower caregiver confidence 
was also significantly associated with increased burden for the 
EQ-5D-Y proxy VAS and FAQLQ-PF Social and Dietary Limitations 
domain. Having experienced a life-threatening event in the past 
12 months was the only significant independent predictor of EQ-
5D-Y proxy utility (B = −0.146, P < .01). This predictor was not sig-
nificant for any other outcomes. When entered into the regression 
models, child's age group, severity group and the age × severity in-
teractions were not significant predictors for any outcomes.
Outcome
Total Sample Aged 4-10 Years Aged 11-15 Years
N Mean (SD) N Mean (SD) N Mean (SD)
EQ-5D Utility
Total 100 0.873 (0.231) 60 0.858 (0.258) 40 0.896 (0.189)
Mild 13 0.863 (0.354) 8 0.778 (0.439) 5 1.000 (0.000)
Moderate 66 0.909 (0.165) 43 0.892 (0.187) 23 0.939 (0.109)
Severe 21 0.768 (0.292) 9 0.766 (0.337) 12 0.771 (0.269)
EQ-5D VAS
Total 100 81.3 (15.9) 60 81.2 (17.2) 40 81.4 (14.0)
Mild 13 81.7 (16.3) 8 79.8 (19.7) 5 84.8 (9.5)
Moderate 66 82.0 (15.5) 43 81.3 (16.6) 23 83.5 (13.4)
Severe 21 78.5 (17.4) 9 82.0 (19.6) 12 75.9 (16.0)
FAQLQ Total
Total 100 3.37 (1.57) 60 3.32 (1.52) 40 3.45 (1.66)
Mild 13 2.73 (1.43) 8 3.15 (1.40) 5 2.06 (1.32)
Moderate 66 3.21 (1.55) 43 3.23 (1.51) 23 3.17 (1.66)
Severe 21 4.28 (1.38) 9 3.88 (1.68) 12 4.58 (1.09)
FAQLQ-Emotional Impact
Total 100 3.14 (1.60) 60 3.07 (1.58) 40 3.24 (1.66)
Mild 13 2.47 (1.25) 8 2.88 (1.24) 5 1.80 (1.03)
Moderate 66 2.99 (1.62) 43 2.97 (1.60) 23 3.02 (1.69)
Severe 21 4.03 (1.45) 9 3.72 (1.74) 12 4.27 (1.21)
FAQLQ-Food Anxiety
Total 100 3.72 (1.65) 60 3.61 (1.60) 40 3.88 (1.72)
Mild 13 3.07 (1.61) 8 3.44 (1.58) 5 2.48 (1.64)
Moderate 66 3.56 (1.62) 43 3.53 (1.57) 23 3.64 (1.76)
Severe 21 4.61 (1.47) 9 4.18 (1.86) 12 4.93 (1.07)
FAQLQ Social Dietary Limitations
Total 100 3.40 (1.63) 60 3.42 (1.55) 40 3.38 (1.78)
Mild 13 2.80 (1.63) 8 3.26 (1.64) 5 2.07 (1.49)
Moderate 66 3.22 (1.59) 43 3.36 (1.55) 23 2.97 (1.66)
Severe 21 4.33 (1.48) 9 3.84 (1.57) 12 4.70 (1.35)
FAIM Total
Total 100 3.78 (0.894) 60 3.80 (0.979) 40 3.75 (0.76)
Mild 13 3.63 (1.10) 8 3.75 (1.17) 5 3.45 (1.07)
Moderate 66 3.69 (0.84) 43 3.74 (0.95) 23 3.60 (0.58)
Severe 21 4.17 (0.87) 9 4.17 (0.98) 12 4.17 (0.83)
Abbreviations: FAIM, Food Allergy Independent Measure; FAQLQ, Food Allergy Quality of Life 
Questionnaire; N, sample size; SD, standard deviation; VAS, visual analogue scale.
TA B L E  2   Proxy-reported measures 
of child PA burden by child age and PA 
severity
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When the regression models were repeated with “lifetime” 
life-threatening events and reactions, the pattern of significant re-
sults was the same for almost all the FAQLQ outcomes, with six or 
more reactions in a lifetime replacing the significant two or more 
reactions in the past 12 months; however, the beta coefficients were 
lower (B = 0.735, 0.874, 0.876 for Total, EI and FA, respectively; all 
P's < .05). For the FAQLQ-SDL domain, the number of “lifetime” re-
actions was not significant but having had a life-threatening event 
in their lifetime was (B = 0.612, P < .05). For FAIM, the number of 
“lifetime” reactions was not significant, but HADS anxiety caseness 
remained significant. For the EQ-5D-Y-VAS the pattern of results 
was the same for “lifetime” reactions as it has been for reactions in 
the “past 12 months” (six or more “lifetime” reactions was significant; 
B = −8.811, P < .05). In the EQ-5D-Y Utility model, “lifetime” reac-
tions was a significant predictor (B = −0.123, P < .05) and life-threat-
ening events also became significant (B = −0.109, P < .05).
4  | DISCUSSION
This survey describes the caregiver-reported burden experienced 
by children with PA in the UK. In line with recent findings, a child's 
sex was not associated with proxy-reported child burden,12 dem-
onstrating that male and female children experience a similar 
level of psychosocial burden due to their PA. Increased PA sever-
ity, however, was significantly associated with increased burden 
among the older children; younger children appear to have a simi-
lar level of burden overall, with less variability due to severity of 
PA. This finding is in line with expectations, given the more uni-
form impact on a young person, for whom the presence of the PA 
may have similar effects regardless of severity, whereas an older 
child may be given more freedom and autonomy and be more able 
to evaluate a situation based on their and their caregiver's percep-
tion of their PA severity.
Caregiver anxiety was significantly correlated with almost all 
proxy-reported measures of child impact, partially supporting pre-
vious research finding maternal anxiety is significantly associated 
with child's proxy-reported HRQL in FA.11,13 However, while care-
giver sex was also significantly associated with child's PA burden 
for almost all FAQLQ outcomes, our findings suggest that male 
caregivers report higher levels of burden experienced by their 
child than female, whereas previous research has found mothers 
reported greater burden for their child than fathers reported.9 It is 
possible that this novel finding is due to previous studies lacking 
male caregivers in their sample; alternatively, this may reflect the 
increase in shared parenting and greater involvement of males in 
childcare. Rates of anxiety were consistent across caregiver sex, 
so the higher burden reported by males was not due to the fact 
males were more anxious.
Relatedly, caregiver anxiety was associated with the child's PA 
reaction history, and “probable clinical” anxiety was only reported 
at levels above UK population norms amongst caregivers report-
ing their child had moderate/severe PA. Given the cross-sectional 
nature of this study, it is not possible to establish whether the 
caregiver's anxiety was caused by their child's experiences with 
PA, or if their anxiety led to higher levels of PA burden being re-
ported. Given the association between caregiver anxiety and 
objective markers of peanut allergy severity, the former seems 
likely, but longitudinal research would be required to confirm this 
definitively.
When controlling for multiple predictors of the child's HRQL 
outcomes, caregiver anxiety and the experience of two or more re-
actions in the past 12 months were the most consistent indepen-
dent predictors of child HRQL. While the descriptive results showed 
increased HRQL burden with increased PA severity, and significant 
correlations between severity and HRQL measures, severity was 
not a significant independent predictor in the multivariate regres-
sion models. This may be due to the association between the child's 
PA severity and caregiver anxiety. The only significant predictor 
of child proxy-reported EQ-5D-Y utility was the objective severity 
indicator of having experienced a life-threatening event. There are 
TA B L E  3   Descriptive statistics of child HRQL outcomes by 
caregiver sex and HADS “probable clinical” anxiety
Outcome/Sex
HADS Probable Anxiety
No (N = 69) Yes (N = 31)
M (SD) M (SD)
EQ-5D-Y Utility
Male (N = 45) 0.925 (0.147) N = 33 0.839 
(0.146) 
N = 12




Male 81 (15) 77 (11)
Female 88 (11) 72 (23)
FAQLQ Total
Male 3.1 (1.4) 4.9 (0.8)
Female 2.8 (1.4) 4.0 (1.8)
FAQLQ-Emotional Impact
Male 2.8 (1.3) 4.9 (0.9)
Female 2.5 (1.3) 3.8 (1.9)
FAQLQ-Food Anxiety
Male 3.6 (1.6) 5.0 (0.7)
Female 3.1 (1.5) 4.4 (1.8)
FAQLQ-Social and Dietary Limitations
Male 3.1 (1.5) 4.9 (0.9)
Female 2.9 (1.5) 4.0 (1.7)
FAIM Total
Male 3.6 (0.9) 4.4 (0.6)
Female 3.6 (0.8) 4.1 (1.0)
Abbreviations: FAIM, Food Allergy Independent Measure; FAQLQ, 
Food Allergy Quality of Life Questionnaire; HADS, Hospital Anxiety 
and Depression Scale; M, mean; N, sample size; SD, standard deviation; 
VAS: visual analogue scale.
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currently no published normative values for the EQ-5D-Y; however, 
there is a published normative value of 0.940 for young adults in 
the UK (aged 18-24 years), and the proxy-reported utilities in the 
current study are lower (0.873 overall) for children than the norm for 
young adults. Further, the results reported here are in line with pre-
viously reported utilities for children with FA. Protudjer et al (2015) 
reported an overall proxy-reported EQ-5D-Y utility of 0.873, com-
pared to 0.875 reported here; likewise, their adolescent utility val-
ues also reflected better HRQL (0.91) than the child utility values 
(0.84).29 Based on review of the literature, this study is the first to 
report caregiver-reported impacts of PA on the EQ-5D-Y, and thus 
may provide a benchmark for future studies using this instrument in 
caregivers of subjects with PA.
Some limitations should be considered when interpreting the re-
sults from this study. All data generated in this study relied upon par-
ent-proxy reports of child HRQL. Previous studies in FA have found 
that parents reported significantly better HRQL for their child than 
the children themselves reported14,15,30; therefore, the results of the 
current study may underestimate the burden experienced by chil-
dren with PA. In addition, self-reported data are subject to recall bias 
and inaccuracy. As discussed above, the study also used a cross-sec-
tional design, so it is not possible to establish cause and effect and 
it is unknown whether caregiver anxiety influences their proxy re-
port of their child's HRQL or whether caregiver perception of their 
child's burden causes their anxiety. The FAQLQ-PF was developed 
for children aged 0 to 12 years; as 28 participants in this study had a 
child aged 13-15 years, it is unclear how this may have affected the 
FAQLQ-PF results. Additionally, like with many studies that collect 
data using online methods, this study did not have clear access to re-
sponse rate data which unfortunately is a common issue. Finally, the 
sample is quite small, data collection was only conducted in the UK, 
and some of the analyses may be underpowered. Future research 
could extend the sample size, traceability of responses and the re-
cruitment to other countries. The inclusion of parent-child dyads and 
a longitudinal design in future research could assess any potential 
differences between parent-proxy reports and child self-reports, 
and begin to unpick the relationship between caregiver anxiety and 
child burden in PA.
This study demonstrated the caregiver-reported burden expe-
rienced by children with PA in the UK, and to our knowledge is the 
first to report caregiver-reported impacts of PA on the widely used 
EQ-5D-Y. The results showed that male and female children experi-
ence a similar level of psychosocial burden due to their PA. For older 
children, increased PA severity is associated with increased burden, 
whereas younger children experience a consistently high level of 
burden unrelated to their PA severity. Caregiver anxiety and sex 
were significantly associated with many proxy-reported measures 
of child impact, with male caregivers reporting more burden expe-
rienced by their child than female caregivers, using disease-specific 
measures. It is clear that further research in a larger sample could ex-
plore and validate this finding. Research could also explore whether 
children with PA in other countries experience a similar level of 
burden. Caregiver anxiety was also associated with the child's PA 
reaction history and severity of PA, suggesting the elevated burden 
reported by caregivers with anxiety may be due to the child's expe-
riences rather than their own anxiety. This issue would benefit from 
further research to investigate whether reducing caregiver anxiety 
may reduce the perceived burden of PA on the child's life.
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